The drug showed therapeutical potential in a recent study (PASPORT-CUSHINGS B2305) where 162 patients were treated with either 2x 600 µg or 2x 900 µg pasireotide s.c. daily. The effectiveness of the treatment was checked by the UFC-value (urinary free cortisol) after six months of treatment. The mean reduction of UFC after six months was 47.9%, which also lead to amelioration of clinical symptoms such as blood pressure, cholesterol value, and weight loss.
Pasireotide was approved by the EMEA in October 2009 and by the FDA in December 2012.
^Boscaro M, Ludlam WH, Atkinson B et al. (January 2009). "Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial". The Journal of Clinical Endocrinology and Metabolism94 (1): 115–22. doi:10.1210/jc.2008-1008. PMID18957506.